Russo Rene, President and CEO of Xilio Therapeutics ($XLO), made one open market purchase of shares worth about $25,000 in the last year, with the most recent on June 16, 2025. This ranks 3,655th among 4,983 insiders, below the average purchase of $1.46 million across about 3.3 transactions. Rene reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 1, 2026 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | M | Common Stock | 44250 | $0.00 | 325,422.0000 | 144,106,869 | 15.74% | 0.03% |
| Jan. 1, 2026 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | M | Restricted Stock Units | 44250 | $0.00 | 88,500.0000 | 144,106,869 | 33.33% | 0.03% |
| Dec. 31, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 1500258 | $0.00 | 1,500,258.0000 | 144,106,869 | 9999.99% | 1.04% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 135134 | $0.00 | 135,134.0000 | 144,106,869 | 9999.99% | 0.09% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 144,106,869 | 9999.99% | 0.07% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 150000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.10% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 144,106,869 | 9999.99% | 0.10% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 350000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.24% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 350000 | $0.00 | 350,000.0000 | 144,106,869 | 9999.99% | 0.24% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 700000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.49% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 700000 | $0.00 | 700,000.0000 | 144,106,869 | 9999.99% | 0.49% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 2075000 | $0.00 | 2,075,000.0000 | 144,106,869 | 9999.99% | 1.44% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 239703 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.17% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 239703 | $0.00 | 239,703.0000 | 144,106,869 | 9999.99% | 0.17% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 473334 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.33% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 473334 | $0.00 | 473,334.0000 | 144,106,869 | 9999.99% | 0.33% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 135134 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.09% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 50041 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.03% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 50041 | $0.00 | 50,041.0000 | 144,106,869 | 9999.99% | 0.03% |
| Nov. 21, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | D | Stock Option (right to buy) | 100000 | $0.00 | 0.0000 | 144,106,869 | 100.00% | 0.07% |
| June 16, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | P | Common Stock | 36289 | $0.68 | 281,172.0000 | 63,465,063 | 14.82% | 0.06% |
| April 15, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 190000 | $0.00 | 190,000.0000 | 63,465,063 | 9999.99% | 0.30% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | M | Common Stock | 44250 | $0.00 | 244,883.0000 | 63,465,063 | 22.06% | 0.07% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | M | Restricted Stock Units | 44250 | $0.00 | 132,750.0000 | 63,465,063 | 25.00% | 0.07% |
| Jan. 1, 2025 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 638000 | $0.00 | 638,000.0000 | 63,465,063 | 9999.99% | 1.01% |
| May 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Stock Option (right to buy) | 474000 | $0.00 | 474,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 1, 2024 | Xilio Therapeutics, Inc. | $XLO | Russo Rene | PRESIDENT AND CEO | A | Restricted Stock Units | 177000 | $0.00 | 177,000.0000 | 0 | 9999.99% | 0.00% |